Vascular Biogenics (NASDAQ:VBLT) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13), Morningstar.com reports. Vascular Biogenics had a negative return on equity of 31.69% and a negative net margin of 2,724.02%. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.25 million.
Shares of Vascular Biogenics stock traded down $0.05 during trading on Wednesday, hitting $1.20. 24,360 shares of the stock traded hands, compared to its average volume of 106,199. The stock has a market cap of $45.21 million, a price-to-earnings ratio of -1.93 and a beta of -0.33. The company has a current ratio of 8.35, a quick ratio of 8.35 and a debt-to-equity ratio of 0.05. Vascular Biogenics has a 52-week low of $0.60 and a 52-week high of $1.90. The firm’s fifty day moving average is $1.30.
A number of analysts have weighed in on VBLT shares. HC Wainwright reiterated a “buy” rating and issued a $3.00 target price on shares of Vascular Biogenics in a research note on Thursday, May 16th. CIBC initiated coverage on Vascular Biogenics in a research note on Thursday, June 27th. They set an “outperform” rating on the stock. Chardan Capital restated a “hold” rating and set a $3.00 price target on shares of Vascular Biogenics in a research note on Tuesday. ValuEngine upgraded Vascular Biogenics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Oppenheimer initiated coverage on Vascular Biogenics in a research note on Thursday, June 27th. They set an “outperform” rating and a $2.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Vascular Biogenics has a consensus rating of “Buy” and an average price target of $2.38.
About Vascular Biogenics
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Recommended Story: Understanding Specialty Certificates of Deposit
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.